New Cancer Treatment Techniques: Antibody Drug Conjugate & Peptide Drug Conjugations
Posted: Dec 17, 2017
The efforts to find a cure for cancers have been ongoing since long time ago. Yet, no effective methods or drugs are discovered by now. Scientists and doctors never stop their steps along this journey with the pains and sufferings of cancer patients echoing in their minds. But with the advance in science and technology, new emerging techniques do make their presence and share their role in the battles against various cancers.
Among them bioconjugation is worthy of mentioning here. As its name suggests, bioconjugation is basically a technique used to form a stable covalent link between at least two different molecular parts of biological origin. Through this technique new chemicals can be made or some biomolecules are able to take on certain personalized new looks. Despite its limitations in specificity, stability and bioavailability, bioconjugation is widely used in biomedical researches given its great potential in cancer treatment.
Of course, when talking about new cancer treatment techniques, we cannot miss antibody drug conjugates and peptide drug conjugates. With application of them, new drugs to cure cancer may be discovered.
Antibody Drug Conjugates (ADCs)
Antibody Drug Conjugates are virtually complex molecules that are composed of an antibody linked to a biologically active cytotoxic payload or drug. Ever since the advent of ADC technique, it has gained remarkable attention and gradually revolutionize the field of cancer chemotherapy.
What makes it stand out among all breakthroughs in the biopharmaceutical industry is ADCs intend to target and kill exclusively the cancer cells and thus spares healthy cells. This differentiates itself from the conventional treatments which will also damage healthy tissues during dose escalation.
Peptide Drug Conjugations
Peptides are considered as an important type of molecules to be derived using the bioconjugation technique. Peptide drug conjugate holds a promising stance in targeted cancer therapy as it enables the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Through synthesis and modification of different categories of peptides, this technique will exert considerable impact on academic research, clinical diagnostics, the production of therapeutics and more.
With continuous innovation in R&D, there are other approaches emerged for the treatment of cancers.
- Loxo Oncology announced global development and commercialization partnership with Bayer for larotrectinib and LOXO-195
- Combining nivolumab with BMS-986205 shows promise in advanced cervical and bladder cancers.
The author is a true follower of biochemistry. BOC Sciences, the company he works for, is a trustworthy supplier of inhibitors.